212Pb in targeted radionuclide therapy: a review
Abstract Background The selective delivery of α-emitting radionuclides is emerging as a highly effective form of cancer therapy. With a short range and high cytotoxicity, α-particles can selectively kill cancerous cells whilst minimising harm to surrounding healthy tissue. As the parent of the α-emi...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-07-01
|
| Series: | EJNMMI Radiopharmacy and Chemistry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41181-025-00362-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849334180658282496 |
|---|---|
| author | Jarred Michael Scaffidi-Muta Andrew David Abell |
| author_facet | Jarred Michael Scaffidi-Muta Andrew David Abell |
| author_sort | Jarred Michael Scaffidi-Muta |
| collection | DOAJ |
| description | Abstract Background The selective delivery of α-emitting radionuclides is emerging as a highly effective form of cancer therapy. With a short range and high cytotoxicity, α-particles can selectively kill cancerous cells whilst minimising harm to surrounding healthy tissue. As the parent of the α-emitter 212Bi, 212Pb has seen increasing therapeutic use on account of its favourable chemistry, half-life, and decay properties. This review comprehensively discusses the clinical development of 212Pb in recent years, particularly its production, chelation chemistry, and therapeutic adoption. Main body Improvements in generator technology and supply have overcome the historically limited availability of 212Pb, enabling a surge of research in the field. Numerous bifunctional chelators have since been developed, which enable facile conjugation of 212Pb to a plethora of tumour targeting carriers. Advancements in nuclear imaging techniques, and the use 203Pb as an imaging surrogate, have enabled accurate biodistribution and dosimetry information to inform preclinical studies. These factors have attracted considerable commercial interest in 212Pb, culminating in the rapid translation of this radionuclide into the clinic, where it is being investigated in the treatment of a range of malignancies. Conclusion Radiotherapy with 212Pb has shown enormous promise in preclinical and clinical studies. While challenges still remain before 212Pb can be more widely adopted, remarkable progress has been made in addressing these. At present, the therapeutic potential of 212Pb is only beginning to be realised. |
| format | Article |
| id | doaj-art-702f3fd9d983472a9009b41c9b62b79c |
| institution | Kabale University |
| issn | 2365-421X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | EJNMMI Radiopharmacy and Chemistry |
| spelling | doaj-art-702f3fd9d983472a9009b41c9b62b79c2025-08-20T03:45:39ZengSpringerOpenEJNMMI Radiopharmacy and Chemistry2365-421X2025-07-0110113410.1186/s41181-025-00362-7212Pb in targeted radionuclide therapy: a reviewJarred Michael Scaffidi-Muta0Andrew David Abell1School of Physics, Chemistry and Earth Sciences, The University of AdelaideSchool of Physics, Chemistry and Earth Sciences, The University of AdelaideAbstract Background The selective delivery of α-emitting radionuclides is emerging as a highly effective form of cancer therapy. With a short range and high cytotoxicity, α-particles can selectively kill cancerous cells whilst minimising harm to surrounding healthy tissue. As the parent of the α-emitter 212Bi, 212Pb has seen increasing therapeutic use on account of its favourable chemistry, half-life, and decay properties. This review comprehensively discusses the clinical development of 212Pb in recent years, particularly its production, chelation chemistry, and therapeutic adoption. Main body Improvements in generator technology and supply have overcome the historically limited availability of 212Pb, enabling a surge of research in the field. Numerous bifunctional chelators have since been developed, which enable facile conjugation of 212Pb to a plethora of tumour targeting carriers. Advancements in nuclear imaging techniques, and the use 203Pb as an imaging surrogate, have enabled accurate biodistribution and dosimetry information to inform preclinical studies. These factors have attracted considerable commercial interest in 212Pb, culminating in the rapid translation of this radionuclide into the clinic, where it is being investigated in the treatment of a range of malignancies. Conclusion Radiotherapy with 212Pb has shown enormous promise in preclinical and clinical studies. While challenges still remain before 212Pb can be more widely adopted, remarkable progress has been made in addressing these. At present, the therapeutic potential of 212Pb is only beginning to be realised.https://doi.org/10.1186/s41181-025-00362-7Lead-212Bismuth-212Targeted radionuclide therapy (TRT)Targeted alpha therapy (TAT)CancerAlpha radiation |
| spellingShingle | Jarred Michael Scaffidi-Muta Andrew David Abell 212Pb in targeted radionuclide therapy: a review EJNMMI Radiopharmacy and Chemistry Lead-212 Bismuth-212 Targeted radionuclide therapy (TRT) Targeted alpha therapy (TAT) Cancer Alpha radiation |
| title | 212Pb in targeted radionuclide therapy: a review |
| title_full | 212Pb in targeted radionuclide therapy: a review |
| title_fullStr | 212Pb in targeted radionuclide therapy: a review |
| title_full_unstemmed | 212Pb in targeted radionuclide therapy: a review |
| title_short | 212Pb in targeted radionuclide therapy: a review |
| title_sort | 212pb in targeted radionuclide therapy a review |
| topic | Lead-212 Bismuth-212 Targeted radionuclide therapy (TRT) Targeted alpha therapy (TAT) Cancer Alpha radiation |
| url | https://doi.org/10.1186/s41181-025-00362-7 |
| work_keys_str_mv | AT jarredmichaelscaffidimuta 212pbintargetedradionuclidetherapyareview AT andrewdavidabell 212pbintargetedradionuclidetherapyareview |